Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286


Pharmacological Scenarios in Translational Research: A Current Multidisciplinary Overview and Possible Developments

Author(s): Andrea Tinelli

Volume 26 , Issue 3 , 2020

Page: [296 - 299] Pages: 4

DOI: 10.2174/138161282603200306092551

Ciebiera M, Vitale SG, Ferrero S, et al. Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy - will it really be a breakthrough? Curr Pharm Des 2020; 26(3): 300-9.
Tinelli A, Kosmas IP, Mynbaev OA, Malvasi A, Sparic R, Vergara D. The biological impact of ulipristal acetate on cellular networks regulating uterine leiomyoma growth. Curr Pharm Des 2020; 26(3): 310-7.
Mynbaev OA, Stark M, Malvasi A, et al. The medical device applied to uterine fibroids morcellation: analysis of critical biological issues and drawbacks from a medical-legal prospective. Curr Pharm Des 2020; 26(3): 318-25.
Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.
Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 486-94.
Mirghani H, Sturgis EM, Aupérin A, Monsonego J, Blanchard P. Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: a systematic review. Oral Oncol 2017; 67: 138-45.
Wollenberg B. Cancer Immunology and HPV. Recent Results Cancer Res 2017; 206: 243-8.
Balmagambetova S, Tinelli A, Mynbaev OA, et al. Human papillomavirus selected properties and related cervical cancer prevention issues. Curr Pharm Des 2020. In Press.
Icardi G, Costantino C, Guido M, et al. Burden and prevention of HPV. knowledge, practices and attitude assessment among pre-adolescents and their parents in Italy. Curr Pharm Des 2020; 26(3): 326-42.
Guido M, Bruno A, Tagliaferro L, et al. The worldwide human papillomavirus vaccination and the impact in a southern Italian region. Curr Pharm Des 2020; 26(3): 343-57.
Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev 2016; 29(3): 449-86.
Nguyen VTN, Simon L. Pertussis: the whooping cough. Prim Care 2018; 45(3): 423-31.
Gkentzi D, Katsakiori P, Marangos M, et al. Maternal vaccination against pertussis: a systematic review of the recent literature. Arch Dis Child Fetal Neonatal Ed 2017; 102(5): F456-63.
Gabutti G, Baccello V, Sandri F, Stefanati A. Rational, safety and effectiveness of pertussis immunization in pregnancy. Curr Pharm Des 2020. In Press.
Di Tommaso S, Cavallotti C, Malvasi A, et al. A qualitative and quantitative study of the innervation of the human non pregnant uterus. Curr Protein Pept Sci 2017; 18(2): 140-8.
Aguilar HN, Mitchell S, Knoll AH, Yuan X. Physiological pathways and molecular mechanisms regulating uterine contractility. Hum Reprod Update 2010; 16(6): 725-44.
Kosmas IP, Malvasi A, Vergara D, Mynbaev OA, Sparic R, Tinelli A. Adrenergic and cholinergic uterine innervation and the impact on reproduction in aged women. Curr Pharm Des 2020; 26(3): 358-62.
Maclaran K, Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond) 2015; 11(2): 169-82.
Pargianas M, Kosmas IP, Apostolopoulou K, et al. Georgiou I. Pathways involved in premature ovarian failure: a systematic review of experimental studies. Curr Pharm Des 2020. In Press
Vergara D, Simeone P, Franck J, et al. Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics. EuPA Open Proteom 2016; 10: 31-41.
Millithaler JF, Cataldo R, De Nunzio G, Alfinito E. Aptamers which target proteins: what proteotronics suggests to pharmaceutics. Curr Pharm Des 2020; 26(3): 363-71.
Rozenblum GT, Lopez VG, Vitullo AD, Radrizzani M. Aptamers: current challenges and future prospects. Expert Opin Drug Discov 2016; 11(2): 127-35.
Parashar A. Aptamers in Therapeutics. J Clin Diagn Res 2016; 10(6): BE01-6.
Vergara D, Verri T, Damato M, et al. A hidden human proteome signature characterizes the epithelial mesenchymal transition program. Curr Pharm Des 2020; 26(3): 372-5.
Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol 2010; 3(3): 385-96.
Roach KM, Bradding P. Ca (2+) signalling in fibroblasts and the therapeutic potential of K(Ca) 3.1 channel blockers in fibrotic diseases. Br J Pharmacol 2019. [Epub ahead of print].
Manfroni G, Ragonese F, Monarca L, et al. New insights on kca3.1 channel modulation. Curr Pharm Des 2020. In press
Amiri A, Tehran MM, Asemi Z, et al. Role of resveratrol in modulating microRNAs in human diseases: from cancer to inflammatory disorder. Curr Med Chem 2019. [Epub ahead of print].
Elshaer M, Chen Y, Wang XJ, Tang X. Resveratrol: an overview of its anti-cancer mechanisms. Life Sci 2018; 207: 340-9.
Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr 2018; 58(9): 1428-47.
Dionigi L, Ragonese F, Monarca L, et al. Focus on the use of resveratrol as adjuvant in glioblastoma therapy. Curr Pharm Des 2020. In Press
Schulman S. Bleeding complications and management on anticoagulant therapy. Semin Thromb Hemost 2017; 43(8): 886-92.
Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 2016; 128(2): 178-84.
Panteleev MA, Andreeva AA, Lobanov AI. Differential drug target selection in blood coagulation: what can we get from computational systems biology models? Curr Pharm Des 2020. In Press

© 2022 Bentham Science Publishers | Privacy Policy